A bnormalities in calcium-phosphorus homeostasis, including significant elevations in serum phosphorus concentrations, are thought to contribute to arterial stiffening, hypertension, and cardiovascular disease (CVD) risk in patients with advanced chronic kidney disease and ESRD that requires maintenance dialysis (1) (2) (3) (4) (5) (6) . Observational data from population-based studies suggested that even serum phosphorus concentrations within the normative range are linearly associated with measures of subclinical arteriosclerosis and the development of incident CVD outcomes (7) (8) (9) (10) (11) (12) . Two cross-sectional studies from patients who underwent cardiac catheterization have further indicated that serum phosphorus concentrations, primarily within the normative range, were directly associated with both the presence and the severity of angiographic coronary artery disease (13, 14) . Moreover, a graded, independent association between serum phosphorus concentrations (again, within the normative range) and recurrent CVD events was reported among a large clinical trial cohort of patients with a previous myocardial infarction (15) .
Supplementation of calcium salts, despite their efficacy and tolerability as a phosphorus-lowering treatment in ESRD, may enhance coronary artery and aortic valve calcification (16, 17) . This observation highlights the need for hyperphosphatemia treatment protocols to balance potential benefits and adverse effects (18 -22) . Phosphorus-lowering drugs that target other cardiovascular risk factors in chronic kidney disease (CKD), simultaneously, including, for example, dyslipidemia (23) , might have additive or synergistic benefits. These findings may also be relevant to populations with less advanced CKD or normal renal function.
Preliminary studies suggested that niacin administration (as niacinamide, niceritrol, or nicotinic acid) could be a useful primary or adjunctive treatment for the marked hyperphosphatemia that is characteristic of ESRD (24 -30) . Several reports from clinical trials of extended-release niacin (ERN) that was given to patients who had dyslipidemia and were free of clinical renal disease and hyperphosphatemia have contained limited additional data noting up to 10% reductions in the serum phosphorus concentrations of actively treated patients (31) (32) (33) (34) . These repeated clinical observations (24 -34) are most plausibly explained by the direct inhibitory effect of niacin compounds on active transport-mediated phosphorus absorption in the mammalian small intestine (35) (36) (37) (38) (39) .
Published studies of patient populations who had dyslipidemia and were receiving ERN that included phosphorus data may have failed to provide information on baseline phosphorus values (33, 34) , and none (31-34) performed repeated measures analyses to examine the potential effects of niacin treatment on serum phosphorus and calcium concentrations, as well as the calcium-phosphorus products.
Focused reexamination of the large, placebo-controlled clinical trial data set assembled by Maccubbin et al. (34) afforded us a unique opportunity to elucidate these and other unresolved issues regarding the impact of niacin given as the fixed-dose combination of ERN and laropiprant (ERN-L), a selective prostaglandin D2 receptor subtype 1 inhibitor that reduces niacininduced flushing (34) or ERN alone on serum phosphorus and calcium concentrations and calcium-phosphorus products. We further evaluated whether there was evidence for significant effect modification by estimated GFR (eGFR), baseline serum phosphorus concentration, the presence of diabetes, or concurrent hepatic hydroxymethyl glutaryl-CoA reductase inhibitor (statin) use when assessing the potential impact of niacin on these routine clinical measures of calcium-phosphorus homeostasis.
Materials and Methods
The analyses described herein were performed as an ancillary study to the completed clinical trial reported by Maccubbin et al. (34) . Details of the parent study design are provided in that previous publication (34) . An extensive discussion of the impact of the niacin versus placebo treatments on lipid, lipoprotein, and apolipoprotein concentrations, as well adverse effects or toxicities associated with active niacin therapy, was also provided in that primary analysis (34) . These findings have not been reproduced here, but we have made available Supplemental Table 1 , which originally appeared in reference (34) , and similar data from the niacin/laropiprant approval process are available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/ tredaptive/emea-combined-h889en.pdf.
Briefly, the parent study was a worldwide, multicenter, double-blind, randomized, placebo-controlled, parallel trial with a 24-week doubleblind treatment period preceded by a 4-week placebo run-in period. Patients who had primary hypercholesterolemia or mixed dyslipidemia and whose serum creatinine was Յ1.7 mg/dl were assigned to initiate treatment with ERN-L, 1 g (one tablet of ERN 1 g/L 20 mg), ERN 1 g, or placebo in a 3:2:1 ratio. Study drug allocation was stratified by ongoing statin use and study site. After 4 weeks of double-blind treatment, dosages were doubled (two tablets), increasing the ERN-L dosages to 2 g/40 mg and the ERN dosage to 2 g for the remaining 20 weeks. Patients were instructed to take study therapy once daily with food, in the evening. There were nine scheduled clinic visits at weeks Ϫ4, Ϫ2, 0 (day 1), 2, 4, 8, 12, 18, and 24.
The final study protocol was reviewed and approved by the appropriate ethics committees/institutional review boards, and all patients provided written informed consent. The study was conducted under the guidelines established by the Declaration of Helsinki and Good Clinical Practice standards.
All of the serum phosphorus, creatinine, calcium, and albumin determinations were performed on fasting blood samples by a central laboratory (PPD Global Central Laboratories, Highland Heights, KY, or Zaventem, Belgium). Serum collected for these measurements was obtained from blood that was allowed to clot for 30 minutes at room temperature and then centrifuged for 15 minutes at 2000 rpm to achieve a clear serum layer over the red cell clot. The serum was immediately transferred into cryovials, refrigerated at 4°C, and shipped overnight under refrigerated conditions to the central laboratory for analyses within several hours of receipt. Concentrations of serum phosphorus, calcium, and albumin were determined using a photometric method. Serum creatinine concentrations were measured by the Jaffe kinetic method. These assays all were performed on the Roche Modular automated clinical chemistry analyzer.
Serum calcium concentration was adjusted for serum albumin concentrations Ͻ4 g/dl using the following formula: Corrected total calcium (mg/dl) ϭ total calcium (mg/dl) ϩ 0.8 ϫ [4 Ϫ serum albumin (g/dl)] (40). eGFR was calculated from the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (41) .
Glycemic status was determined before randomization for the parent study and designated "normal," "impaired," or "diabetic" on the basis of medical history, laboratory evaluations, and clinical judgment. Only the assignment of "diabetes" was used for our analyses comparing diabetic and nondiabetic strata.
Statistical Analysis
The primary objective of this post hoc analysis was to examine the 24-week phosphorus-lowering effects using the changes in serum phosphorus concentrations on the basis of measurements taken at baseline (0) and at 4, 8, 12, 18, and 24 weeks. The secondary objective was to examine whether these effects varied by prespecified subgroups, including eGFR of Ͻ60 versus Ն60 ml/min per 1.73 m 2 , serum phosphorus Ͼ3.5 versus Յ3.5 mg/dl, the presence of diabetes, or concomitant statin (hepatic hydroxymethyl glutaryl-CoA reductase inhibitor) use. The primary efficacy parameter was the change from baseline in serum phosphorus concentrations averaged across weeks 12, 18, and 24. The average across weeks 12 through 24 was used in the analysis (consistent with the analysis of the primary lipid end points reported previously [34] ) because it was expected that the concentrations of serum phosphorus would stabilize by week 12 (i.e., after 8 weeks on 2 g of ERN). Additional parameters included changes from baseline in serum calcium concentrations and the product of serum calcium-phosphorus concentrations, also averaged across weeks 12 through 24.
A repeated measures analysis of phosphorus concentrations was conducted using data recorded at 5 study weeks (weeks 4, 8, 12, 18, and 24), with fixed effects for treatment-by-week interaction, gender-byweek interaction, concomitant statin use-by-week interaction, baseline phosphorus-by-week interaction, country, and random patient effect. The correlation between the responses of the same patient at different time points was modeled using an unstructured covariance matrix. Separate covariance matrices were specified for each of the three treatment groups. The average differences in serum phosphorus change between treatment groups from baseline across weeks 12 through 24 was estimated using the appropriate contrasts from the model. A similar approach was used for the analyses of serum calcium concentrations and calcium-phosphorus products.
Potential treatment effect modification by eGFR of Ͻ60 versus Ն60 ml/min per 1.73 m 2 , serum phosphorus Ͼ3.5 versus Յ3.5 mg/dl, the presence of diabetes, or concomitant statin use was evaluated by constructing the within-subgroup estimates (with 95% confidence intervals [CIs]) of the between-treatment differences. Baseline descriptive statistics included means Ϯ SD, quantiles, and frequencies. Characteristics at baseline were generally comparable across the treatment arms. Changes in serum phosphorus and calcium concentrations, as well as calcium -phosphorus products, were expressed as means, with 95% CIs.
Results
As (Table 2 ) and calcium-phosphorus products. Figure 1 illustrates the time course of the observed treatment effects by ERN-L and ERN on serum phosphorus concentrations, relative to placebo. Both niacin preparations achieved their maximal impact by the eighth week of treatment, and these effects were then sustained throughout the remainder of the 24-week study. Table 3 shows that within the subgroup of 215 patients whose eGFR was Ͻ60 ml/min, ERN-L treatment (n ϭ 110) changed mean Ϯ SD baseline serum phosphorus (3.38 Ϯ 0.45) by Ϫ0.44 mg/dl (95% CI Ϫ0.50 to Ϫ0.37), and ERN (n ϭ 67) treatment changed mean baseline serum phosphorus (3.41 Ϯ 0.49) by Ϫ0.38 mg/dl (95% CI Ϫ0.47 to Ϫ0.29), whereas the placebo group (n ϭ 38) experienced a 0.03-mg/dl mean increase (95% CI Ϫ0.09 to 0.15) from its baseline serum phosphorus (of 3.46 Ϯ 0.45 mg/dl). These results (see Table 3 ) were similar to the effects (95% CI) on serum phosphorus in patients (n ϭ 1332) with an eGFR Ն60 ml/min.
There was also no evidence of effect modification by the presence of diabetes, concomitant statin use, or baseline serum phosphorus being Ͼ3.5 versus Յ3.5 mg/dl. Among patients with diabetes, ERN-L treatment (n ϭ 126) changed mean Ϯ SD baseline serum phosphorus (3.42 Ϯ 0.47) by Ϫ0.35 mg/dl (95% CI Ϫ0.43 to Ϫ0.28 mg/dl), and ERN (n ϭ 72) treatment changed mean baseline serum phosphorus (3.48 Ϯ 0.44) by Ϫ0.36 mg/dl (95% CI Ϫ0.45 to Ϫ0.28 mg/dl), whereas the placebo group (n ϭ 38) experienced a 0.01-mg/dl mean increase (95% CI Ϫ0.11 to 0.14 mg/dl) from its baseline serum phosphorus (of 3.55 Ϯ 0.51 mg/dl). Within the nondiabetic stratum, ERN-L treatment (n ϭ 635) changed mean baseline serum phosphorus (3.32 Ϯ 0.46) by Ϫ0.39 mg/dl (95% CI Ϫ0.42 to Ϫ0.36 mg/dl), and ERN (n ϭ 446) treatment changed mean baseline serum phosphorus (3.30 Ϯ 0.48) by Ϫ0.35 mg/dl (95% CI Ϫ0.39 to Ϫ0.31 mg/dl), whereas the placebo group (n ϭ 230) experienced a 0.04-mg/dl mean increase (95% CI Ϫ0.00 to 0.08 mg/dl) from its baseline serum phosphorus (of 3.35 Ϯ 0.48 mg/dl). Statin users who were treated with ERN-L (n ϭ 509) experienced a mean Ϯ SD change in their baseline serum phosphorus (3.35 Ϯ 0.47) of Ϫ0.36 mg/dl (95% CI Ϫ0.39 to Ϫ0.32 mg/dl), and ERN (n ϭ 344) treatment changed their mean baseline serum phosphorus (3.30 Ϯ 0.46) by Ϫ0.36 mg/dl (95% CI Ϫ0.40 to Ϫ0.32 mg/dl), whereas the placebo group (n ϭ 178) had a 0.03-mg/dl mean increase (95% CI Ϫ0.02 to 0.07 mg/dl) from its baseline serum phosphorus (of 3.38 Ϯ 0.49 mg/dl). Among nonusers of statins, ERN-L treatment (n ϭ 252) changed mean baseline serum phosphorus (3.32 Ϯ 0.44) by Ϫ0.42 mg/dl (95% CI Ϫ0.47 to Ϫ0.37 mg/dl), and ERN (n ϭ 174) treatment changed mean baseline serum phosphorus (3.37 Ϯ 0.49) by Ϫ0.34 mg/dl (95% CI Ϫ0.41 to Ϫ0.28 mg/dl), whereas the placebo group (n ϭ 90) experienced a 0.06-mg/dl mean increase (95% CI Ϫ0.00 to 0.12 Table 3 . Change from baseline serum phosphorus and calcium-phosphorus product across weeks 12 through 24, with repeated measurements at weeks 4, 8, 12, 18, and 24, comparing eGFR Ͻ60 and eGFR Ն60 ml/min per 
Discussion
Our detailed analyses of the phosphorus and calcium data that were collected from 1547 patients during a 24-week intervention confirmed and extended the findings from three reports published between 1998 and 2000 (31) (32) (33) . We demonstrated conclusively that ERN-L and ERN alone caused a sustained approximately 11% reduction in serum phosphorus (Figure 1 ), accompanied by an approximately 12% lowering of the calcium-phosphorus product, without raising serum calcium concentrations. None of these effects was altered by laropiprant; neither was there any evidence of effect modification by eGFR being Ͻ60 or Ն60 ml/min, a serum phosphorus of Ͼ3.5 versus Յ3.5 mg/dl, the presence of clinical diabetes, or concomitant statin use.
Extant publications on the phosphorus-lowering impact of niacin compounds in patients with ESRD (24 -30) , particularly once-daily ERN (26 -29) , revealed the hypophosphatemic effects of niacin to be of the same magnitude achieved by calcium acetate, sevelamer, or lanthanum when these agents are administered thrice daily and timed requisitely to meals (16 -21,42) .
Animal model data highlight plausible mechanisms-especially fecal loss (37)-that account for the observed phosphorus-lowering effects of niacin preparations (36 -40) . Approximately 50% of net phosphorus absorption occurs in the duodenum and jejunum via an active transport pathway through the epithelial Na-Pi co-transporters contained in abundantly expressed, "ready to use" vesicles located within the small intestinal brush border (30, 35) . The energy required for this active phosphorus transport is provided by basolateral Na-K-ATPase (35). Eto et al. (38) demonstrated in a rat model of ESRD that nicotinamide inhibits small intestinal Na-Pi2b expression, reducing phosphorus absorption and preventing the progressive increase in serum phosphorus that is associated with renal failure. Another investigation in healthy rats showed, independently, that nicotinamide inhibits sodium-dependent intestinal phosphorus co-transport (36) .
Abnormalities in calcium-phosphorus homeostasis, including significant elevations in serum phosphorus concentrations, are thought to contribute to arterial stiffening, hypertension, and CVD risk in patients with advanced CKD and ESRD that requires maintenance dialysis (16 -18) . Marked hyperphosphatemia in ESRD and the very increased phosphorus concentrations of advanced (i.e., stage 4) CKD both have been associated with the development of CVD, particularly fatal outcomes (1-6). Additional reports from populations with high CVD risk-myocardial infarction survivors (15) and patients with type 2 diabetes and hypertension (43)-have described linear associations between serum phosphorus concentrations within the normative range and arteriosclerotic outcomes, especially recurrent, fatal CVD events. Observational data from population-based studies further suggested that normative serum phosphorus concentrations are linearly associated with measures of subclinical arteriosclerosis and the development of incident CVD outcomes (7) (8) (9) (10) .
Such observational data (1-10,15,43) have engendered calls (44, 45) for controlled clinical trials to test the hypothesis that serum phosphorus-lowering treatment will reduce CVD mortality, primarily. Two very prominent "blueprints" for such trials that target patients within specific eGFR ranges of stages 3 to 4 CKD (15 to 44 and 20 to 45 ml/min per 1.73 m 2 ) were recently published (44, 45) . Both of these communications referenced the major commercial phosphorus binders-sevelamer, calcium acetate, and lanthanum-whereas neither trial rationalization blueprint (44,45) nor a subsequent extensive clinical practice guideline (42) referenced any of the published literature (24 -34) on the phosphorus-lowering efficacy of niacin compounds. Our extensive findings demonstrating ERN-induced phosphorus lowering contrast starkly with the very limited data available from small, brief studies of lanthanum (46) , sevelamer (47) , and calcium acetate (47) given to patients with stages 3 and 4 CKD. For example, both sevelamer (up to 6.4 g/d), and calcium acetate (up to 5.28 g/d) failed to lower serum phosphorus in a pilot study of 40 patients who had CKD and whose mean creatinine clearance was 36.8 ml/min and mean baseline serum phosphorus concentrations were 3.53 mg/dl (47) . Moreover, given the onerous pill burden that thricedaily phosphorus binder treatment imposes on patients with ESRD (48)-severely limiting their compliance (48)-it is an uncertain proposition that patients with less advanced, asymptomatic stages 3 to 4 CKD will comply adequately with binders.
Conclusions
In light of the secondary CVD prevention data from the crystalline niacin arm of the Coronary Drug Project (49), the established ameliorative effects of ERN on lipoprotein metabolism (31) (32) (33) (34) , and the systematic underrepresentation of patients with an eGFR Ͻ60 ml/min in randomized, controlled trials to reduce CVD outcomes (50) , the data on niacin presented herein suggest that an ERN treatment arm deserves the utmost consideration for any future CVD prevention trials that target patients with stages 3 to 4 CKD. 
